The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis
Abstract
BACKGROUND: Current pharmacotherapy for allergic rhinitis (AR) does not totally ameliorate all symptoms for all patients. Residual symptoms could be due to nasal neuronal hyperresponsiveness caused by stimulation of the ion channel transient receptor potential vanilloid 1 (TRPV1). SB-705498 is a TRPV1 antagonist that has been developed in an intranasal formulation for treatment of AR. METHODS: This randomized, double-blind, 3-way incomplete block crossover study evaluated the effects of 8 days treatment with SB-705498 12 mg alone, SB-705498 12 mg plus fluticasone propionate 200 μg (FP), FP 200 μg alone or placebo on allergen-induced symptoms in 70 patients with AR. The primary endpoint was total nasal symptom score (TNSS), expressed as mean over 4 hours or maximum TNSS during allergen challenge in the Vienna Challenge Chamber on 8th day of treatment. RESULTS: At the end of treatment, there were no differences in allergen-induced mean TNSS between SB-705498 alone and placebo or between SB-705498 plus FP and FP alone. Treatment with FP and SB-705498 plus FP resulted in a significant decrease in TNSS vs. placebo. Mean (90% CI) treatment differences in TNSS over 0 - 4 hours were: SB-705498 - placebo: -0.2 (-0.9, 0.4); SB-705498 plus FP - FP: 0.7 (0.2, 1.2); FP - placebo: -2.9 (-3.4, -2.5); SB-705498 plus FP - placebo: -2.3 (-2.8, -1.8). SB-705498 had no impact on diary card symptoms, nasal airflow or Rhinoconjunctivitis Quality of Life Questionnaire scores. SB-705498 was well tolerated and pharmacokinetics exposure results supported the dosing regimen. CONCLUSION: SB-705498 12 mg for 8 days did not alleviate the allergen-induced symptoms of AR, or provide additional relief of symptoms when in combination with FP. Despite engagement of the TRPV1 receptor there was no translation to clinical efficacy, suggesting redundancy in symptom pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this respect, numerous randomized, placebo-controlled clinical trials have been conducted using parallel-group or crossover designs in order to test the efficacy of drugs with immediate therapeutic activity, such as antihistamines,1050-1053 or with prophylactic therapeutic potential, such as topical steroids,1054-1056 novel anti-inflammatory compounds,1057-1060 or probiotics.1061”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1057]
Citations
Cites
Naclerio, R. M. (2003) · Cited by 985
Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire☆☆☆★
Juniper, E. F., Thompson, A. K., Ferrie, P. J., & Roberts, J. N. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70380-5 · Cited by 376
The role of the nervous system in rhinitis
Sarin, S., Undem, B., Sanico, A., & Togias, A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.09.013 · Cited by 245
Interpretation of rhinoconjunctivitis quality of life questionnaire data
Juniper, E. F., Guyatt, G. H., Griffith, L. E., & Ferrie, P. J. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)70135-5 · Cited by 244
Allergic rhinitis: Direct and indirect costs
Blaiss, M. S. (2010) · Allergy and Asthma Proceedings · doi:10.2500/aap.2010.31.3329 · Cited by 220
The transient receptor potential vanilloid 1: Role in airway inflammation and disease
Geppetti, P., Materazzi, S., & Nicoletti, P. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.063 · Cited by 187
Allergic rhinitis and the common cold – high cost to society
Hellgren, J., Cervin, A., Nordling, S., Bergman, A., & Cardell, L. O. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02269.x · Cited by 183
Allergic rhinitis and impairment issues in schoolchildren: a consensus report
Michael S. Blaiss, O. B. O. T. G. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x13266 · Cited by 146
International Primary Care Respiratory Group (IPCRG) Guidelines: Management of allergic rhinitis
Price, D. B., Bond, C. M., Bouchard, J., Costa, R., Keenan, J. M., Levy, M. L., Orru, M., Ryan, D. P., Walker, S. M., & Watson, M. C. (2005) · Primary Care Respiratory Journal · doi:10.1016/j.pcrj.2005.11.002 · Cited by 133
Horak, F., Stübner, U. P., Zieglmayer, R., & Harris, A. G. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.124657 · Cited by 111
Self-citation
Cited by
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Nilius, B., & Szallasi, A. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008268 · Cited by 506
“9) did not provide any symptomatic relief in patients with seasonal allergic rhinitis (Bareille et al., 2013).”
BackgroundAdverse Effects of Cigarette and Noncigarette Smoke Exposure on the Autonomic Nervous System
Middlekauff, H. R., Park, J., & Moheimani, R. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1201 · Cited by 240
Khalid, S., Murdoch, R., Newlands, A., Smart, K., Kelsall, A., Holt, K., Dockry, R., Woodcock, A., & Smith, J. A. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.01.038 · Cited by 194
Self-citation
Metadata
- Authors
- Bareille, P., Murdoch, R. D., Denyer, J., Bentley, J., Smart, K., Yarnall, K., Zieglmayer, P., Zieglmayer, R., Lemell, P., & Horak, F.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- Medical University of Vienna (AT)
- University of Vienna (AT)
- Venue
- Int. Journal of Clinical Pharmacology and Therapeutics
- Publisher
- Dustri-Verlgag Dr. Karl Feistle
- Published
- 2013-07-01
- Volume
- 51
- Issue
- 07
- Pages
- 576-584
- ISSN
- 0946-1965 (ISSN-L)
- OpenAlex
- W2086120371
- Cited by
- 41
- References
- 31
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 6 · 2016: 2 · 2015: 6 · 2014: 7
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Clinical Pharmacology and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- TRPV1 antagonists, allergic rhinitis, fluticasone propionate, nasal symptom score, nasal hyperreactivity, combination therapy, drug tolerability, pharmacokinetics, quality of life, nasal airflow, rhinoconjunctivitis
- MeSH terms
- Fluticasone, Administration, Intranasal, Adult, Androstadienes, Austria, Double-Blind Method, Drug Therapy, Combination, Female, Rhinitis, Allergic, Seasonal, Humans, Male, Pyrrolidines, Urea, Treatment Outcome, Cross-Over Studies, Anti-Allergic Agents, TRPV Cation Channels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. https://app.cochat.ai/papers/10.5414/cp201890
- The paper
- Bareille, P., Murdoch, R. D., Denyer, J., Bentley, J., Smart, K., Yarnall, K., Zieglmayer, P., Zieglmayer, R., Lemell, P., & Horak, F. (2013). The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp201890
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.